Uma Mahadevan1, Millie D Long2, Sunanda V Kane3, Abhik Roy4, Marla C Dubinsky5, Bruce E Sands5, Russell D Cohen6, Christina D Chambers7, William J Sandborn8. 1. Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California. Electronic address: uma.mahadevan@ucsf.edu. 2. Division of Gastroenterology and Hepatology, Data Management Center, University of North Carolina, Chapel Hill, North Carolina. 3. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 4. Division of Gastroenterology, Kaiser Permanente, San Leandro, California. 5. Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. 6. Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, Chicago, Illinois. 7. Department of Pediatrics, University of California San Diego, La Jolla, California. 8. Division of Gastroenterology and Hepatology, University of California San Diego, La Jolla, California.
Abstract
BACKGROUND & AIMS: Pregnant women with inflammatory bowel disease (IBD) may require biologic or thiopurine therapy to control disease activity. Lack of safety data has led to therapy discontinuation during pregnancy, with health repercussions to mother and child. METHODS: Between 2007 and 2019, pregnant women with IBD were enrolled in a prospective, observational, multicenter study across the United States. The primary analysis was a comparison of 5 outcomes (congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infant infections) among pregnancies exposed vs unexposed in utero to biologics, thiopurines, or a combination. Bivariate analyses followed by logistic regression models adjusted for relevant confounders were used to determine the independent effects of specific drug classes on outcomes of interest. RESULTS: Among 1490 completed pregnancies, there were 1431 live births. One-year infant outcomes were available in 1010. Exposure was to thiopurines (n = 242), biologics (n = 642), or both (n = 227) vs unexposed (n = 379). Drug exposure did not increase the rate of congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infections during the first year of life. Higher disease activity was associated with risk of spontaneous abortion (hazard ratio, 3.41; 95% confidence interval, 1.51-7.69) and preterm birth with increased infant infection (odds ratio, 1.73; 95% confidence interval, 1.19-2.51). CONCLUSIONS: Biologic, thiopurine, or combination therapy exposure during pregnancy was not associated with increased adverse maternal or fetal outcomes at birth or in the first year of life. Therapy with these agents can be continued throughout pregnancy in women with IBD to maintain disease control and reduce pregnancy-related adverse events. ClinicalTrials.gov, Number: NCT00904878.
BACKGROUND & AIMS: Pregnant women with inflammatory bowel disease (IBD) may require biologic or thiopurine therapy to control disease activity. Lack of safety data has led to therapy discontinuation during pregnancy, with health repercussions to mother and child. METHODS: Between 2007 and 2019, pregnant women with IBD were enrolled in a prospective, observational, multicenter study across the United States. The primary analysis was a comparison of 5 outcomes (congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infant infections) among pregnancies exposed vs unexposed in utero to biologics, thiopurines, or a combination. Bivariate analyses followed by logistic regression models adjusted for relevant confounders were used to determine the independent effects of specific drug classes on outcomes of interest. RESULTS: Among 1490 completed pregnancies, there were 1431 live births. One-year infant outcomes were available in 1010. Exposure was to thiopurines (n = 242), biologics (n = 642), or both (n = 227) vs unexposed (n = 379). Drug exposure did not increase the rate of congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infections during the first year of life. Higher disease activity was associated with risk of spontaneous abortion (hazard ratio, 3.41; 95% confidence interval, 1.51-7.69) and preterm birth with increased infant infection (odds ratio, 1.73; 95% confidence interval, 1.19-2.51). CONCLUSIONS: Biologic, thiopurine, or combination therapy exposure during pregnancy was not associated with increased adverse maternal or fetal outcomes at birth or in the first year of life. Therapy with these agents can be continued throughout pregnancy in women with IBD to maintain disease control and reduce pregnancy-related adverse events. ClinicalTrials.gov, Number: NCT00904878.
Authors: Gabriella Bröms; Fredrik Granath; Anders Ekbom; Karin Hellgren; Lars Pedersen; Henrik T Sørensen; Olof Stephansson; Helle Kieler Journal: Clin Gastroenterol Hepatol Date: 2015-09-12 Impact factor: 11.382
Authors: Uma Mahadevan; Douglas C Wolf; Marla Dubinsky; Antoine Cortot; Scott D Lee; Corey A Siegel; Thomas Ullman; Sarah Glover; John F Valentine; David T Rubin; Jocelyn Miller; Maria T Abreu Journal: Clin Gastroenterol Hepatol Date: 2012-11-28 Impact factor: 11.382
Authors: Mette Julsgaard; Lisbet A Christensen; Peter R Gibson; Richard B Gearry; Jan Fallingborg; Christian L Hvas; Bo M Bibby; Niels Uldbjerg; William R Connell; Ourania Rosella; Anne Grosen; Steven J Brown; Jens Kjeldsen; Signe Wildt; Lise Svenningsen; Miles P Sparrow; Alissa Walsh; Susan J Connor; Graham Radford-Smith; Ian C Lawrance; Jane M Andrews; Kathrine Ellard; Sally J Bell Journal: Gastroenterology Date: 2016-04-08 Impact factor: 22.682
Authors: Gary R Lichtenstein; Paul Rutgeerts; William J Sandborn; Bruce E Sands; Robert H Diamond; Marion Blank; Jennifer Montello; Linda Tang; Freddy Cornillie; Jean-Frédéric Colombel Journal: Am J Gastroenterol Date: 2012-05-22 Impact factor: 10.864
Authors: Katarina Mitrova; Barbora Pipek; Martin Bortlik; Ludek Bouchner; Jan Brezina; Tomas Douda; Tomas Drasar; Pavel Drastich; Premysl Falt; Pavel Klvana; Vaclav Leksa; Ales Novotny; Pavel Svoboda; Jan Skorpik; Jan Ulbrych; Marek Veinfurt; Blanka Zborilova; Milan Lukas; Dana Duricova Journal: Therap Adv Gastroenterol Date: 2021-08-07 Impact factor: 4.409